R-107-H

R-107-H is a specific formulation variant of R-107, an oral extended-release tablet of racemic ketamine developed by Douglas Pharmaceuticals and its subsidiary Tasman Therapeutics. It is being developed for the treatment of treatment-resistant depression (TRD). The R-107 program utilizes a proprietary controlled-release technology designed to provide sustained plasma levels of ketamine, which may improve therapeutic efficacy and reduce the dissociative side effects associated with rapid-acting ketamine formulations. Its primary mechanism of action involves the antagonism of the N-methyl-D-aspartate (NMDA) receptor, thereby modulating glutamate and GABA neurotransmission. R-107-H has been evaluated in Phase 1 clinical studies, specifically in a randomized crossover study assessing its relative bioavailability compared to other formulation variants such as R-107-P under fasting conditions.

Other names

ketamine extended-release tablet